Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.69 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775367 | 0.92 | HRH4 (0.61) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL12605115 | 0.89 | HRH4 (0.60) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL1774659 | 0.84 | HRH4 (0.77) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL12605103 | 0.82 | HRH4 (0.63) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL12605048 | 0.81 | HRH4 (1.00) | HRH4KCNH2HRH3 | |
| SCHEMBL12605095 | 0.81 | HRH4 (0.73) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL1774257 | 0.81 | HRH4 (0.73) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL5152060 | 0.81 | HRH4 (0.73) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL1774905 | 0.81 | HRH4 (0.63) | HRH4NUDT1KCNH2HRH3 | |
| SCHEMBL605280 | 0.81 | HRH4 (0.76) | HRH4NUDT1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885NUDT1 17/4885KCNH2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.